Early Clinical Experience with Onasemnogene Abeparvovec in Spinal Muscular Atrophy (SMA) Type 2 Patients at a Single Center

被引：0
|
作者：
Matesanz, Susan
Kichula, Elizabeth
机构：
来源：
NEUROLOGY | 2020年 / 94卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
4855
引用
收藏
页数：3
相关论文
共 50 条
  • [21] COST-EFFECTIVENESS OF NUSINERSEN AND ONASEMNOGENE ABEPARVOVEC FOR INFANTILE-ONSET SPINAL MUSCULAR ATROPHY (TYPE I SMA) IN THE US
    Thokala, P.
    Stevenson, M.
    Kumar, V. M.
    Ren, S.
    Chapman, R.
    Ellis, A.
    Rind, D.
    VALUE IN HEALTH, 2019, 22 : S337 - S338
  • [22] Onasemnogene-abeparvovec administration to premature infants with spinal muscular atrophy
    Brown, Stephen M.
    Ajjarapu, Aparna S.
    Ramachandra, Divya
    Blasco-Perez, Laura
    Costa-Roger, Mar
    Tizzano, Eduardo F.
    Sumner, Charlotte J.
    Mathews, Katherine D.
    ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY, 2024, 11 (11): : 3042 - 3046
  • [23] Onasemnogene Abeparvovec-xioi: Gene Therapy for Spinal Muscular Atrophy
    Stevens, Debra
    Claborn, Melanie K.
    Gildon, Brooke L.
    Kessler, Tiffany L.
    Walker, Cheri
    ANNALS OF PHARMACOTHERAPY, 2020, 54 (10) : 1001 - 1009
  • [24] Onasemnogene Abeparvovec Gene-Replacement Therapy (GRT) in Pre-symptomatic Spinal Muscular Atrophy (SMA)
    Schultz, M.
    Swoboda, K.
    Farrar, M.
    McMillan, H.
    Parsons, J.
    Kernbauer, E.
    Farrow, M.
    Ogrinc, F.
    Kavanagh, S.
    Feltner, D.
    McGill, B.
    Spector, S.
    L'Italien, J.
    Sproule, D.
    Strauss, K.
    ANNALS OF NEUROLOGY, 2019, 86 : S133 - S133
  • [25] Risdiplam experience following onasemnogene abeparvovec in individuals with spinal muscular atrophy: a multicenter case series
    Kuntz, N.
    Svoboda, M.
    Leon-Astudillo, C.
    Byrne, B.
    Krueger, J.
    Kwon, J.
    Sieburg, C.
    Castro, D.
    NEUROMUSCULAR DISORDERS, 2023, 33 : S162 - S162
  • [26] Gene Therapy for Spinal Muscular Atrophy (SMA): A Review of Current Challenges and Safety Considerations for Onasemnogene Abeparvovec (Zolgensma)
    Ogbonmide, Tolu
    Rathore, Rajni
    Rangrej, Shahid B.
    Hutchinson, Stedrea
    Lewis, Marcia
    Ojilere, Stephenie
    Carvalho, Victoria
    Kelly, Irenaissia
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2023, 15 (03)
  • [27] Onasemnogene abeparvovec gene-replacement therapy (GRT) in pre-symptomatic spinal muscular atrophy (SMA)
    Schultz, M.
    Swoboda, K.
    Farrar, M.
    McMillan, H.
    Parsons, J.
    Kernbauer, E.
    Farrow, M.
    Ogrinc, F.
    Kavanagh, S.
    Feltner, D.
    McGill, B.
    Spector, S.
    L'Italien, J.
    Sproule, D.
    Strauss, K.
    NEUROMUSCULAR DISORDERS, 2019, 29 : S183 - S183
  • [28] Outcomes in patients with spinal muscular atrophy (SMA) and four or more SMN2 copies treated with onasemnogene abeparvovec: findings from RESTORE
    Finkel, R.
    Benguerba, K.
    Gehani, M.
    Raju, D.
    Faulkner, E.
    LaMarca, N.
    Servais, L.
    NEUROMUSCULAR DISORDERS, 2023, 33 : S133 - S133
  • [29] MATCHING-ADJUSTED INDIRECT COMPARISON OF ONASEMNOGENE ABEPARVOVEC AND NUSINERSEN FOR THE TREATMENT OF SPINAL MUSCULAR ATROPHY TYPE 1 (SMA1)
    Bischof, M.
    Lorenzi, M.
    Lee, J.
    Dabbous, O.
    VALUE IN HEALTH, 2020, 23 : S623 - S624
  • [30] SOCIETAL COSTS OF SPINAL MUSCULAR ATROPHY TYPE 1 FOR PATIENTS TREATED WITH ONASEMNOGENE ABEPARVOVEC OR NUSINERSEN IN THE UNITED KINGDOM
    Kleintjens, J.
    Patel, A.
    van Keep, M.
    Srivastava, K.
    McHale, P.
    Affinito, S.
    Bischof, M.
    VALUE IN HEALTH, 2024, 27 (06) : S135 - S135
12345